Speakers

Speakers Line-Up

Keynote Speaker

John Wilbanks
Chief Commons Officer, Sage Bionetworks, Senior Fellow,
Ewing Marion Kauffman Foundation and FasterCures, USA
TEDGlobal 2012 Speaker on “Let’s Pool Our Medical Data” 

Speakers Line-up
Li Ling Liu, Director
Good Registration Management (GRM)Researcher, Deputy Director General Office, Taiwan Food and Drug Administration (TFDA), Taiwan

Eva Kopecna
Senior Director Generics Regulatory Affairs Global OTC
Teva Pharmaceuticals International GmbH, Switzerland  

Qing Xi
Head of Government Affairs, Market Access & Communications, Pfizer, China
Jean-François Baladi
Senior Executive, Health Economics and Market Access
Novartis Pharma K.K., Japan

Manish R Garg
Medical Director (Singapore, Malaysia and Brunei)
MSD Pharma (Singapore) Ptd Ltd, Singapore

Akhmal Yusof
Chief Executive Officer
Clinical Research Malaysia, Malaysia
Pierce Chow
Professor
Duke-NUS Graduate Medical School/Senior Consultant, Division of Surgical Oncology, National Cancer Centre Singapore / Senior Consultant, Department of Hepatopancreatobiliary/Transplant Surgery, Singapore General Hospital
Vincenzo Teneggi
Senior Medical Director
D3 (Drug Discovery & Development) A*STAR, Singapore
Asita de Silva
Professor in Pharmacology, Director, Clinical Trials Unit, Faculty of Medicine
University of Kelaniya, Sri Lanka
Kurt Lackovic
CEO
Cancer Trials Australia
Ritika Bajaj
Associate Director, Global Clinical Trial Operations
MSD Pharmaceuticals, India
Dr C.S. Chen
Executive Director - Cancer Center, Acting Chief of Medicine
Shanghai Jiahui International Hospital, China and and Consultant, Massachusetts General Hospital, Boston, USA

Yashaswi Gupta
Medical Science Liaison
Novo Nordisk, Singapore

Tay Salimullah
Global Strategic Projects Leader, Real World Evidence
Novartis Pharma AG, Switzerland
PJ Chen
Vice President, Head of Medical and Clinical Affairs Centre
United BioPharma, Taiwan
Yooni Kim
Executive Director, Asia Operations
Novotech, South Korea
Kevin Cheong
Director, Clinical Operations - Asia
ALMAC Pharmaceutical Services, LLC, Singapore
Craig R. Rayner
President
d3 Medicine, A Certara Company,
Adjunct Associate Professor, Monash University - Monash Institute of Pharmaceutical Sciences, Australia
Mary Pan
Vice President General Management and Business Development Asia Pacific
ICON Plc, Singapore
Mrunalini Jagtap
Data Management Lead
Singapore Institute for Clinical Sciences, A*STAR
Shubhra Bansal
Consulting Learning Partner
Pan Asian Clinical Research Association (PACRA) and Director, Apprentice Learning Solutions

Wei Yuan
Senior Biostatistician
Singapore Clinical Research Institute, Singapore

Ivan John Clement
Data Scientist
MSD Innovation Hub, Singapore

Roshan Padbidri
Chief Operating Officer (COO)
Anidan Group Pte Ltd, Singapore

Alex Matter
CEO
Experimental Therapeutics Centre & D3, A*STAR, Singapore

Dr. Stephanie Danandjaja, MBA
APAC Medical Director, Established Product
Abbott

Speakers Profile

Keynote Speaker

John Wilbanks
Chief Commons Officer, Sage Bionetworks, Senior Fellow, Ewing Marion Kauffman Foundation and FasterCures, USA
TEDGlobal 2012 Speaker on “Let’s Pool Our Medical Data” 

John Wilbanks seeks to transform and innovate medical research by accelerating data sharing between clinical studies. As the Chief Commons Officer at Sage Bionetworks, he is in-charge of figuring out how to design policies and technologies that allow health and biological data to be broadly share between patients, clinicians and data analysis.

Sage Bionetworks has put their open source toolkit innovation to the test by designing an application to conduct a set of Sage Bionetworks mobile research studies enrolling more than 100,000 participants in less than two years and integrated into more than 25 studies outside of Sage, including the US Precision Medicine Initiative

To view John’s talk at TEDGlobal 2012, click   https://www.ted.com/talks/john_wilbanks_let_s_pool_our_medical_data

Speakers Line-up

Qing Xi
Head of Government Affairs, Market Access & Communications
Pfizer, China

As the Senior Director of Government Affairs, Market Access & Communications of Pfizer China, Mr. XI is responsible for central and local government affairs, market access, policy advocacy, CSR, communications and media relations to support all business and function in China. As a member of Pfizer China Leadership Team, he reports to Regional President of Pfizer China directly.

From Oct. 2009 to Feb. 2016, Mr. XI was the Head of Communications in Pfizer China, leading Communications to develop and implement communication strategies and projects.

Before Pfizer acquired Wyeth in 2009, Mr. Xi was the Public Relation Director of Wyeth China. And before joining Wyeth in 2004, he had been working at Intel China for above 7 years in Public Relation & External Affairs.

He is now co-chairing the Communication Working Group of R&D Based Pharmaceutical Association Committee (RDPAC).

Mr. Xi got his EMBA degree from Shanghai Europe International Business School (CEIBS) and the Bachelor Degree from Shanghai Jiao-Tong University.


Jean-François Baladi
Senior Executive, Health Economics and Market Access
Novartis Pharma K.K., Japan

Jean-Francois Baladi is currently the senior executive, HealthEconomics and Market Access at Novartis Pharma K.K. (Japan). In this role, he oversees the pricing, market access and health economics and outcome research areas. Previously, Jean-Francois was the global head of health economics and market access for Novartis Oncology for 10 years, role in which he established and then led the function whose role was the determination of the global pricing and market access strategy for Novartis Oncology products as well as the health economics strategy and execution. Earlier in his career, Jean -Francois was Director of Healthcare Policy and Pharmacoeconomics at Novartis Canada. He had started his career in health economics as a research associate at the Canadian Coordinating Office for Technology Assessment. Jean-Francois holds an MBA from Concordia University in Montreal (Canada). He authored a number of peer-reviewed publications on pharmacoeconomics guidelines, Quality of life research, patient reported outcomes and various economic evaluations of pharmaceutical products.


Asita de Silva
Professor in Pharmacology, Director, Clinical Trials Unit, Faculty of Medicine
University of Kelaniya, Sri Lanka

Professor Asita de Silva has held many positions in academic medicine over the last 24 years. He is a Clinical Pharmacologist, and is currently Professor of Pharmacology at the Faculty of Medicine, University of Kelaniya, Sri Lanka. He established Sri Lanka’s pioneering academic clinical research centre in the same university in collaboration with the Clinical Trial Service Unit, University of Oxford in 2005. Over the last decade, Prof de Silva has lead Sri Lanka’s clinical research initiative through this unit establishing international collaborations. His work has leveraged Sri Lanka’s excellent healthcare structure and clear regulatory policies with great success. Winner of Presidential awards for research, Prof de Silva has been a member of the National Steering Committee for clinical trials in the country for over five years.


Vincenzo Teneggi
Senior Medical Director
D3 (Drug Discovery & Development) A*STAR, Singapore

Vincenzo has more than 25 years global experience of drug development within major pharmaceutical companies as Wellcome, Glaxo-Wellcome, GSK, Novartis and Roche in Europe, North America and Asia Pacific.

He has held a number of positions such as Clinical Medical Expert, Head of Drug Surveillance, Head of Phase II-IV Clinical Research and Head of Early Development & Clinical Pharmacology for Asia Pacific. Through these roles he has gained an extensive and deep knowledge of all phases of clinical drug development in multiple therapeutic areas including cardiovascular, liver, lung diseases, neurosciences, virology and oncology, as well as clinical pharmacology, drug safety/pharmaco-vigilance and biomarker strategy in early clinical trials.

Vincenzo received his medical degree, as well his Lung Disease and Internal Medicine specialist qualifications from the University of Rome “La Sapienza”. He has published scientific papers in major journals and presented at numerous conferences as well as being the co-author of book chapters and named inventor on patent applications.

He is a member of: the Physicians-Surgeons and Dentists Association of Rome, the American Society of Clinical Oncology, the American Society for Clinical Pharmacology and Therapeutics.


Kurt Lackovic
CEO
Cancer Trials Australia

Dr Kurt Lackovic is CEO of Cancer Trials Australia, a not-for-profit enabler of clinical trials, incorporated in 2003.  Kurt has a PhD in chemistry and post-doc experience in medical genomics and early stage drug discovery.  Kurt has extensive expertise in leading complex academic and clinical programs, strong connections to industry, and strategic linkages to senior executives in Government and major teaching Hospitals. Kurt is a Graduate of the Australian Institute of Company Directors, and a member of the Licensing Executives Society of Australia & New Zealand and AusBiotech.


Akhmal Yusof
Chief Executive Officer
Clinical Research Malaysia, Malaysia

Dr Akhmal Yusof is an experienced leader from a global research based biopharmaceutical company. He graduated from the Royal College of Surgeons in Ireland in 1992 and practiced medicine in the public and private hospitals for almost 10 years. He later ventured into the medical insurance industry as Medical Manager in one of the biggest medical insurance provider in Malaysia. He was later head hunted to lead the Medical Department in a global research-based biopharmaceutical organization for over 12 years. His main forte in the industry is clinical research management & regulatory, medical and government affairs. He now leads Clinical Research Malaysia (CRM) as the Chief Executive Officer. CRM is a non-profit company owned by the Ministry of Health Malaysia, that functions as a one stop centre for industry-sponsored research.


Ritika Bajaj
Associate Director, Global Clinical Trial Operations
MSD Pharmaceuticals, India

Dr. Ritika Bajaj is Associate Director, Global Clinical Trial Operations at MSD Pharmaceutical, India and a member of the Indian society for Clinical Research since 2007

Dr. Ritika has over 17 years of clinical Research industry experience. She has held leadership positions with reputed multinational Pharma and Biotech companies like Eli Lilly and Biogen Inc. and has worked in several Therapeutic areas including Diabetes Care, Oncology, critical Care, Neurology and hemophilia contributing to the clinical development and life cycle management of several promising drugs in her career.

Ritika has received her advanced GCP training from the Vienna School of Clinical Research and is also a Six-Sigma green belt in process improvement.

Outside of clinical Operations she has contributed to learning and development of clinical research professionals, in the Asia Pac region through various training programs, and has been a speaker at several national and international forums.


Tay Salimullah
Global Strategic Projects Leader, Real World Evidence
Novartis Pharma AG, Switzerland

Tay is Director Global Pricing and Market Access in Cell and Gene Therapies at Novartis Pharma Switzerland. Responsible for developing the market access strategy; value story; and pricing strategy across multiple indications for one-time potentially curative therapies for patients with relapsed refractory forms of hematological cancers.

Tay recently lead project HARMONY: an external industry leading public-private-partnership to shape outcomes, reimbursement and policy in Europe. HARMONY is the largest big data for better outcomes funded (€40M) programme. The project aims to foster better access and care for patients with various Hematological Malignancies with the use of big data as well as drive R&D efficiency.

Tay joined Novartis in 2013 as Market Access Director Region Europe in General Medicines. Prior to joining Novartis Tay worked at Pfizer for 11 years where he held several positions of increasing responsibilities within commercial, market access and strategy development. In 2009 Tay completed his Global Health Fellowship: in-field healthcare systems experience (USAID) in Malawi to scale eHealth organization to provide HIV solutions for 10% of the population. He has also worked in Asia as market access consultant and for a multibillion dollar private investment group to provide solutions for the low-middle income healthcare consumers across Asia.


Pierce Chow
Professor
Duke-NUS Graduate Medical School/Senior Consultant, Division of Surgical Oncology, National Cancer Centre Singapore / Senior Consultant, Department of Hepatopancreatobiliary/Transplant Surgery, Singapore General Hospital

Pierce Chow is Co-Director (Surgical) of the Comprehensive Liver Cancer Clinic at NCCS and Senior Consultant Surgeon in HPB and Transplant Surgery at SGH. He is concurrently Professor and Course Director at DukeNUS Medical School Singapore, Adjunct Faculty at GIS and Research Director at IMCB.

Pierce has researched extensively on hepatocellular carcinoma (HCC) and leads collaborative research on the genomic heterogeneity of HCC and applications in precision medicine. He co-founded the Asia-Pacific Hepatocellular Carcinoma Trials Group in 1997 and has been the protocol chair of 5 multi-national trials. In 2012 the NMRC conferred him the National Outstanding Clinician-Scientist Award for improving clinical outcomes of patients with his research on Liver Cancer.

Pierce was awarded the NMRC Translational-Clinical Research Grant for the Flagship Program in Liver Cancer in 2016 and has commenced the multi-national PLANET study (Precision Medicine in Liver Cancer Asia-Pacific Network).


PJ Chen
Vice President, Head of Medical and Clinical Affairs Centre
United BioPharma, Taiwan

PJ Chen is VP of global clinical development and president of Taiwan at United Neuroscience. United Neuroscience (UNS) is a clinical-stage biotech company dedicated to the development of innovative therapeutics for Alzheimer’s Disease and other neurodegenerative disorders. In this role, PJ oversees the clinical development programs and business operation in Taiwan office.

PJ joined UNS with experiences in early phase drug development at Harvard medical school (HMS) and Massachusetts General Hospital (MGH), drug development and project/data management with AstraZeneca and project management, clinical monitoring and commercial operation functions in CRO industry including PPD, Parexel and WuXiPRA. PJ received his graduate degree from Massachusetts Institute of technology in biomedical imaging.


Kevin Cheong
Director, Clinical Operations - Asia
ALMAC Pharmaceutical Services, LLC, Singapore

Kevin Cheong is Director, Clinical Operations at Almac, where he oversees operational staff and service delivery from the company’s operational centers in Singapore and Japan.  Being one of the pioneer member of the Singapore leadership team, Kevin was involved in the setting up of the Almac’s Singapore Facility. The facility is the first in Singapore to provide Primary Production Services to the region.

Prior to joining Almac, Kevin served as the Operations Director for Fisher Clinical Services, where he managed financial and operational performance for all clinical studies and grew key accounts by more than 50 percent.  Kevin also managed and expanded Fisher’s regional Singapore facility, established cold chain operations, and implemented a new building management system that enabled web-based visibility and wireless temperature and humidity monitoring.

A frequent speaker, Kevin has led workshops on supply chain management and optimization, continuous process improvement, and radio-frequency identification in the logistics industry.

Kevin holds a Bachelor of Science in Computing from the University of Portsmouth and is certified in Production and Inventory Management by the American Production and Inventory Control Society.


Craig R. Rayner
President
d3 Medicine, A Certara Company,
Adjunct Associate Professor, Monash University - Monash Institute of Pharmaceutical Sciences, Australia

Dr. Rayner has more than 15 years of drug development experience. His past appointments include leadership roles in Clinical Pharmacology and Early development (Roche), Clinical development (CSL-Behring), in Business Development/Licensing as Global Due Diligence Director (Roche) and as an academic researcher in clinical pharmacology and infectious disease research (Monash University).

Dr. Rayner has extensive experience in early and late development of therapeutics, regulatory interaction experience with all major global health authorities, multiple filings and accountability for numerous due diligences, active support of negotiations, deal making and integration activities. He holds an Adjunct Associate Professorship in Pharmaceutical Science (Monash University), and is broadly published in clinical pharmacology and also infectious diseases.


Yooni Kim
Executive Director, Asia Operations
Novotech, South Korea

At Novotech, Dr. Kim is responsible for overseeing Novotech’s operations and project delivery within the Asia region. Dr. Kim is very experienced in Asia’s drug development industry, having managed operations for South Korea, Taiwan, China, Hong Kong, Singapore, Malaysia, Indonesia, Thailand, the Philippines and Japan. Prior to joining Novotech, Dr. Kim was Director of Operations for North Asia at leading global CRO and has worked at various positions in clinical development, medical affairs and pharmacovigilance at GSK. Dr. Kim has spoken widely regarding the current landscape of clinical development in Asia. Dr. Kim is a trained pharmacist and received doctorate degree of medicine from Seoul National University, specializing in Preventive Medicine and Epidemiology.


Dr C.S. Chen
Executive Director - Cancer Center, Acting Chief of Medicine
Shanghai Jiahui International Hospital, China and and Consultant, Massachusetts General Hospital, Boston, USA

Prior to joining Jiahui, Dr. Chen was the Professor of Medicine, Pediatrics and Basic Science; Chief, Division of Medical Oncology & Hematology and Bessie Emanuel Endowed Chair for Clinical Oncology Research at Loma Linda University and Medical Center, in California, USA. 

Dr. Chen graduated from China Medical University and completed Ph.D. and postdoctoral training in molecular oncology (Pathobiology Program) at University of Minnesota, USA.  He received his Internal Medicine internship and residency training at the Washington University Medical Center, Barnes Hospital in St Louis, Missouri followed by Medical Oncology fellowship at Fred Hutchinson Cancer Research Center (FHCRC) and University of Washington in Seattle.  In 1997, he was the recipient of first E Donnell Thomas Award at FHCRC for his research work.

During 98’-03’, He launched stem cell transplant program and served as the director for the adult transplant program at LLU, California, USA.  By 03’, Dr. Chen was recruited by National University of Singapore (NUS) and National University Hospital as a senior consultant and associate professor.  He continued clinical practice, expanded stem cell transplant program and translational research. 

In 2007, Dr. Chen was recruited back to LLU, California as the chief of the division of hematology and medical oncology and facilitated the opening of a state-of-art cancer center.  He also launched the LLU Cancer Center Biospecimen Bank in 08’ and established multiple research collaboration in translational medicine.

During his nearly 20 years at Loma Linda and Singapore, in addition to multiple leadership role in program development, Dr. Chen was the primary investigator for multiple clinical research trials including malignant hematology and solid tumors over the two decades, and has published more than 65 peer-reviewed papers in PNAS, Leukemia, Blood, Cancer Research, Oncotarget, and Journal of Clinical Oncology.


Mary Pan
Vice President General Management and Business Development Asia Pacific
ICON Plc, Singapore

 

 

  • Head of APAC for ICON, in charge of a region of 13 countries and 2900 employees
  • 20 years’ leadership in Global drug development and Medical Affairs (Pfizer, Crucell / J&J) based out of the USA, EU, and Asia
  • Grew global CRO in Asia from employee #1 to 150 and 8 countries in 2.5 years as managing director
  • Head of Strategy and Business Development for $1.2 Billion portfolio
  • Pharma, Biotech, Medical Device, CRO experience
  • MD ed, LLM (law), MBA, PMP, Six Sigma Black Belt

Mrunalini Jagtap
Data Management Lead
Singapore Institute for Clinical Sciences, A*STAR

During her previous stints with pharmaceutical and ITES/CRO organizations, Mrunalini has gained expertise in leading global clinical data management projects conducted across US, Europe and Asia-Pacific to successful completion. Currently she is associated with SICS where she is leading data management practices for observational studies in academia. She is passionate about streamlining processes and continuous improvement. Mrunalini has completed Masters in Data Science and Analytics from Royal Holloway University of London, UK and is trained in Lean Six Sigma Black Belt. She is a certified clinical data manager (CCDM) by SCDM and a certified project management professional (PMP) by PMI, USA. Mrunalini has authored five articles and also presented on diverse topics at various international conferences in Singapore, India and Germany.


Shubhra Bansal
Consulting Learning Partner
Pan Asian Clinical Research Association (PACRA) and Director, Apprentice Learning Solutions

Ms. Shubhra Bansal is a Consulting Learning Partner - Pan Asian Clinical Research Association (PACRA) and Director- Apprentiice Learning Solutions. Shubhra has been in Pharmaceutical research Industry for 18 years with depth of experience. She holds a Master of Science in Medical Elementology and Toxicology from Hamdard University, New Delhi. Shubhra started her career in University research in 1999 and progressed into clinical research in year 2000. Starting from basics of Clinical research as a Clinical Research Associate , she had reached to the position of Director, Asia Pacific -Clinical Management in a Multinational Organization. She has wide experience of various Therapeutics areas across Asia Pacific countries. During her entire career, Shubhra has been instrumental in leading and providing the support, guidance and mentorship to team members and her reports. She has been leading training for the department across Asia pacific and has worked as core contributor on global training initiatives during her career.

She is a certified Trainer from Life Sciences Skill Sector Council, New Delhi; Member of Indian Society of Clinical Research (ISCR) and Member of Leaders Excellence at Harvard Business Square.


Wei Yuan
Senior Biostatistician
Singapore Clinical Research Institute, Singapore

Ms. Wei Yuan is a senior biostatistician from Singapore Clinical Research Institute, a MOH holding academic research organization. Primarily she provides biostatistics support to clinical trials, including study design, protocol development, sample size justification, randomization, database review, statistical analysis plan and report, manuscript writing and publication. She has involved in the first antiviral clinical trial against acute dengue in Singapore and the recently completed randomised clinical trial of prophylactic platelet transfusion for adult dengue patients with thrombocytopenia (ADEPT) published in Lancet medical journal. Ms. Wei also has great interests in health technology assessment and is doing a part time degree with University of York in this topic.


Ivan John Clement
Data Scientist
MSD Innovation Hub, Singapore

Ivan Clement is a data scientist with Merck & Co. (MSD), focused on applying advanced analytics, machine learning, and mathematical modeling techniques on pre-clinical and -omics data, health economics read-outs, and novel forms of real-world evidence.

He has held research attachments with the Massachusetts Institute of Technology (MIT), the Singapore-MIT for Research and Technology (SMART), and the Mechanobiology Institute, building experimental and computational platforms to interrogate cancer pathophysiology on multiple biological scales – using cutting-edge techniques in machine learning and mathematical modeling.

He was formerly a computational scientist with Eli Lilly and Company, building models of drug distribution and action in support of drug development programs and FDA regulatory submissions. While in Lilly, he has also supported the development and the application of systems pharmacology modeling in diabetes and immuno-oncology drug development programs.


Roshan Padbidri
Chief Operating Officer (COO)
Anidan Group Pte Ltd, Singapore

Roshan Padbidri has had the opportunity of having assumed a variety of roles in the clinical trial enterprise in the past 14 years. In his former role as Regional Clinical Operations Excellence Consultant of Sanofi Asia-Pacific regional HQ, he was responsible for the clinical operations of medical affairs studies including oversight, execution, budgeting, inspection readiness and quality improvement visits. Currently, he is Vice-President and General Manager of Anidan Group Pte Ltd where he oversees strategy, operations, finance, business growth and development.

As the former Clinical Study Manger of Takeda Global Development and Research Centre (Asia) Pte Ltd, he oversaw global clinical development programmes and focused on study feasibility, protocol development, CRO selection, monitoring, budget management, training and quality management.  

Prior to this appointment, he was Clinical Leader and Manager of Parexel International Sdn Bhd. In this regional role, he was responsible for clinical study assessment and initiation, project implementation, trial performance reporting to the sponsors and financial tracking.

He was the former Manager, Clinical Development of Novartis India Ltd at the International Clinical Research Operations(ICRO). He was responsible for clinical operations, monitoring, SOP writing, systems expert and training coordinator for APAC.

Formerly, he served the term in the training council at the Indian Society of Clinical Research (ISCR) where he developed and delivered training modules for national workshops for advanced GCP courses. He served as visiting faculty at the following institutes; Pharmaceutical Experts Association (PEXA), Institute of Clinical Research India (ICRI), Centre for Advancement in Health Sciences (CAHS) and Academy of Clinical Excellence(ACE).

He has a graduate degree in Microbiology and is a Post graduate in Biochemistry from the university of Mumbai.


Alex Matter
CEO
Experimental Therapeutics Centre & D3, A*STAR, Singapore

Alex Matter is CEO of the Experimental Therapeutics Centre since April 2009 and since January 2012 CEO of the newly created D3 platform, A*STAR, Singapore. Previously, he had spent five and a half years as Director of the Novartis Institute for Tropical Diseases (NITD), from October 2003 to February 2009. Prior to this role, Dr. Matter was Global Head of Oncology Research for Novartis Pharmaceuticals Corporation. Dr. Matter played an important role in the success of several anticancer drugs, including Gleevec/Glivec®and more recently, Tasigna®, building and leading the teams that discovered these and several other anticancer drugs as well as one HIV protease inhibitor (Reyataz®) that is marketed by another company.

Dr. Matter received his medical degree from the University of Basel. He also had fellowships at the Swiss National Science Foundation and the Swiss Academy for Medical Sciences. He has published more than 100 scientific articles and several book chapters in the area of oncology and hematology. He is emeritus Professor of the Medical Faculty of the University Basel and an Honorary Adjunct Professor of the Department of Pharmacology, YLL School of Medicine, NUS in Singapore. He is also a member of the Board of the Health Sciences Authorities in Singapore.

He is a member of the American Association for Cancer Research, and member of the Board of Curiox, a Singapore-based start up company. He is also a chair/member of several Scientific Advisory Boards. He is an elected member of the Swiss Academy of Medical Sciences.

Dr. Matter is the recipient of the Life-time Achievement Award from IBC Life Sciences, the 13th Warren-Alpert prize and the AACR-Bruce F. Cain Memorial Award. Recently he was awarded the 2013 Szent-Györgyi Prize from the US National Foundation for Cancer Research.


Manish R Garg
Medical Director (Singapore, Malaysia and Brunei)
MSD Pharma (Singapore) Ptd Ltd, Singapore

Manish Garg is a physician with MD in Clinical Pharmacology. He is currently Medical Director for MSD Malaysia, Singapore and Brunei. He has a rich experience with Pharmaceutical Industry for more than 13 years. He has actively contributed in Medical Affairs (MA) in both innovator (Bayer and Abbott) and Generic companies (Unichem and Glenmark).  He has been in a Country MA Role and Asia Pacific Regional Therapy Area Expert (Oncology) Role. Prior to joining Pharmaceutical Industry he was in clinical practice treating patients in outpatient setting. He has also worked as a lecturer in a Medical School attached to a Tertiary Hospital. He has been involved in research and has several publications to his credit in peer reviewed journals during post graduate period. He also has received awards and gold medals for his research.


Yashaswi Gupta
Medical Science Liaison
Novo Nordisk, Singapore

Currently working as a medical science liaison at Novo Nordisk Singapore, Dr Yashaswi Gupta is an expert at analysing clinical data to obtain commercial insights. Armed with medical & management degrees, her real strength lies in providing rich insights to healthcare professionals through latest scientific & clinical data. She has handled entire project management activities for clinical trials in different parts of Asia. Her diverse experience in healthcare consulting, clinical research, and medical affairs allows her to grasp key opportunities for launching a new product. Passionate about developing new & innovative ways to address constraints faced in clinical trials, she works closely with multi-disciplinary teams at Novo Nordisk to drive KOL engagement and to support research initiatives.


Dr. Stephanie Danandjaja, MBA
APAC Medical Director, Established Product
Abbott

Stephanie is a physician with experience in working with multinational companies in the US, Indonesia and Singapore for the last 15 years in the areas of Medical Affairs, Clinical Research, Regulatory, Pharmacovigilance and Business Development.  

She joined Aventis Indonesia in 2000 as Medical Manager. In 2003, she became Schering Plough’s Medical & Regulatory Director and was seconded to Global Medical Operations in SP Headquarters, NJ, US. She was also part of the Global Working group for R&D and Medical Affairs merger – combining both functions and streamlining after the merger with Organon. In 2007, she joined Sanofi Indonesia as Medical & Regulatory Director, and then added Business Development into her scope in 2009 – leading M&A and integrating CHC business into the affiliate.

She relocated to Sanofi Asia Regional office in Singapore as Regional Medical Excellence in 2010. In 2013 her role was expanded to cover Strategic Planning and Medical Operations until early this year. She is currently APAC Medical Director for Abbott Established Products, as well as Adjunct Associate Professor in Rutgers School of Health Professions. She is also Steering Committee Advisor for ASEAN Drug Information Associations.